#news #biotech Phase 1 data backs Cyclacel’s plans for CDK2/9 inhibitor

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Phase 1 data backs Cyclacel’s plans for CDK2/9 inhibitor .Just over a year ago, Cyclacel was hit by a late-stage failure in leukemia that sent its shares into a tailspin and pushed an early-stage CDK inhibitor into the spotlight as its most promising candidate. Now, that CDK drug has shown it can stabilize disease in advanced cancers and is ready to be twinned with AbbVie’s leukemia drug Venclexta in phase 2.

from FierceBiotech: Biotech https://ift.tt/2J0exXw